Cancer (Solid Tumors)
15
9
9
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.7%
1 terminated out of 15 trials
75.0%
-11.6% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (15)
Comparative Effectiveness of Verbal Instruction Versus Simulation Video Education Among Cancer Patients Undergoing Radiation Therapy
Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin
Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions
SBRT-LATTICE-PATHY
TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer
Is the 1939 Cancer Act Fit for Purpose in the Modern Technology Era?
WellSpan-THRIVE Cancer QOL Study
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Immune Adverse Events Registry in Onco-Hematologic Patients Treated With Immunotherapy
N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial
Cardiovascular Risk in Children With Chronic Conditions Study
Salutare One Referral Software Impact on Multi-Disciplinary Team (MDT) Meetings Effectiveness and Safety
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)